September 18th 2024
Your daily dose of the clinical news you may have missed.
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Surv.AI Says: Real-World Insights Into the Journey for Patients With Pulmonary Arterial Hypertension
View More
Low-dose Rivaroxaban plus Aspirin Effective in CAD/PAD Regardless of Multimorbidity, Polypharmacy
July 15th 2021In patients with stable vascular disease from the COMPASS trial, the combination of rivaroxaban and aspirin effectively reduced ischemic events despite multiple comorbidities and polypharmacy.
SGLT2 Inhibitor Empagliflozin Found Safe, Effective for HFpEF in Landmark EMPORER-Preserved Trial
July 7th 2021Empagliflozin, already indicated to improve outcomes in patients with HFrEF, reduced risk of a composite of CV death or hospitalization for HF in adults HFpEF, marking a potential therapeutic milestone.